乳房微生物群与乳腺癌：现状与未来

doi:10.3760/cma.j.cn371439-20230627-00007

摘要/Abstract

摘要：

近年来研究发现,乳腺癌组织与正常乳房组织之间存在不同的乳房微生物群。乳房微生物群与乳腺癌的发生、发展有着密切关系,其作用机制包括影响雌激素水平、脂质代谢、免疫调节和炎症反应等。调整饮食、合理使用抗生素及口服益生菌等可调节乳房微生物群,是预防和治疗乳腺癌的新方向。

关键词: 乳腺肿瘤, 微生物群, 肿瘤微环境, 雌激素类

Abstract:

In recent years, studies have found that breast microbiota differs between breast cancer tissue and normal breast tissue. Breast microbiota is closely related to the occurrence and development of breast cancer, and its mechanism includes affecting estrogen levels, lipid metabolism, immune regulation, and inflammatory response. Adjusting diet, rational use of antibiotics and oral probiotics can regulate breast microbiota, which is a new direction for the prevention and treatment of breast cancer.

Key words: Breast neoplasms, Microbiota, Tumor microenvironment, Estrogens

顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.

Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.

参考文献 33

[1]	Mikó E, Kovács T, Sebő É, et al. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored[J]. Cells, 2019, 8(4): 293. DOI: 10.3390/cells8040293.
[2]	Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial topography of the healthy human lower respiratory tract[J]. mBio, 2017, 8(1): e02287-16. DOI: 10.1128/mBio.02287-16.
[3]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494): 973-980. DOI: 10.1126/science.aay9189. pmid: 32467386
[4]	Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J]. Cancer Discov, 2018, 8(4): 403-416. DOI: 10.1158/2159-8290.CD-17-1134. pmid: 29567829
[5]	Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associated with different breast cancer types[J]. Front Microbiol, 2018, 9: 951. DOI: 10.3389/fmicb.2018.00951. pmid: 29867857
[6]	Uzan-Yulzari A, Morr M, Tareef-Nabwani H, et al. The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies[J]. BMC Med, 2020, 18(1): 281. DOI: 10.1186/s12916-020-01751-2. pmid: 33081767
[7]	Shui L, Yang X, Li J, et al. Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy[J]. Front Immunol, 2019, 10: 2989. DOI: 10.3389/fimmu.2019.02989. pmid: 32010123
[8]	Vitorino M, Alpuim Costa D, Vicente R, et al. Local breast microbiota: a "new" player on the block[J]. Cancers (Basel), 2022, 14(15): 3811. DOI: 10.3390/cancers14153811.
[9]	Tzeng A, Sangwan N, Jia M, et al. Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer[J]. Genome Med, 2021, 13(1): 60. DOI: 10.1186/s13073-021-00874-2. pmid: 33863341
[10]	Hieken TJ, Chen J, Chen B, et al. The breast tissue microbiome, stroma, immune cells and breast cancer[J]. Neoplasia, 2022, 27: 100786. DOI: 10.1016/j.neo.2022.100786.
[11]	Parida S, Sharma D. Microbial alterations and risk factors of breast cancer: connections and mechanistic insights[J]. Cells, 2020, 9(5): 1091. DOI: 10.3390/cells9051091.
[12]	Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer[J]. Cell, 2022, 185(8): 1356-1372.e26. DOI: 10.1016/j.cell.2022.02.027. pmid: 35395179
[13]	Klann E, Williamson JM, Tagliamonte MS, et al. Microbiota composition in bilateral healthy breast tissue and breast tumors[J]. Cancer Causes Control, 2020, 31(11): 1027-1038. DOI: 10.1007/s10552-020-01338-5.
[14]	Smith A, Pierre JF, Makowski L, et al. Distinct microbial communities that differ by race, stage, or breast-tumor subtype in breast tissues of non-Hispanic Black and non-Hispanic White women[J]. Sci Rep, 2019, 9(1): 11940. DOI: 10.1038/s41598-019-48348-1. pmid: 31420578
[15]	Pollet RM, D'Agostino EH, Walton WG, et al. An atlas of β-glucuronidases in the human intestinal microbiome[J]. Structure, 2017, 25(7): 967-977.e5. DOI: 10.1016/j.str.2017.05.003. pmid: 28578872
[16]	Sellitto A, D'Agostino Y, Alexandrova E, et al. Insights into the role of estrogen receptor β in triple-negative breast cancer[J]. Cancers (Basel), 2020, 12(6): 1477. DOI: 10.3390/cancers12061477.
[17]	Shively CA, Register TC, Appt SE, et al. Consumption of Mediterranean versus Western diet leads to distinct mammary gland microbiome populations[J]. Cell Rep, 2018, 25(1): 47-56.e3. DOI: 10.1016/j.celrep.2018.08.078. pmid: 30282037
[18]	Soto-Pantoja DR, Gaber M, Arnone AA, et al. Diet alters entero-mammary signaling to regulate the breast microbiome and tumorigenesis[J]. Cancer Res, 2021, 81(14): 3890-3904. DOI: 10.1158/0008-5472.CAN-20-2983. pmid: 34083249
[19]	罗澜, 陈创, 李昕倩, 等. 细菌与乳腺癌的关系[J]. 国际肿瘤学杂志, 2021, 48(5): 292-295. DOI: 10.3760/cma.j.cn371439-20200629-00056.
[20]	Giallourou N, Urbaniak C, Puebla-Barragan S, et al. Characterizing the breast cancer lipidome and its interaction with the tissue microbiota[J]. Commun Biol, 2021, 4(1): 1229. DOI: 10.1038/s42003-021-02710-0. pmid: 34707244
[21]	Dadsena S, Hassan DG, Holthuis JCM. Unraveling the molecular principles by which ceramides commit cells to death[J]. Cell Stress, 2019, 3(8): 280-283. DOI: 10.15698/cst2019.08.196. pmid: 31440742
[22]	Portincasa P, Bonfrate L, Vacca M, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis[J]. Int J Mol Sci, 2022, 23(3): 1105. DOI: 10.3390/ijms23031105.
[23]	Schulthess J, Pandey S, Capitani M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages[J]. Immunity, 2019, 50(2): 432-445.e7. DOI: 10.1016/j.immuni.2018.12.018. pmid: 30683619
[24]	Salimi V, Shahsavari Z, Safizadeh B, et al. Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment[J]. Lipids Health Dis, 2017, 16(1): 208. DOI: 10.1186/s12944-017-0593-4. pmid: 29096636
[25]	Bagheri Z, Moeinzadeh L, Razmkhah M. Roles of microbiota in cancer: from tumor development to treatment[J]. J Oncol, 2022, 2022: 3845104. DOI: 10.1155/2022/3845104.
[26]	Chen F, Yang J, Guo Y, et al. Integrating bulk and single-cell RNA sequencing data reveals the relationship between intratumor microbiome signature and host metabolic heterogeneity in breast cancer[J]. Front Immunol, 2023, 14: 1140995. DOI: 10.3389/fimmu.2023.1140995.
[27]	Rao Malla R, Marni R, Kumari S, et al. Microbiome assisted tumor microenvironment: emerging target of breast cancer[J]. Clin Breast Cancer, 2022, 22(3): 200-211. DOI: 10.1016/j.clbc.2021.09.002.
[28]	Liwinski T, Zheng D, Elinav E. The microbiome and cytosolic innate immune receptors[J]. Immunol Rev, 2020, 297(1): 207-224. DOI: 10.1111/imr.12901. pmid: 32658330
[29]	Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J]. JAMA Oncol, 2019, 5(12): 1774-1778. DOI: 10.1001/jamaoncol.2019.2785. pmid: 31513236
[30]	Kim H, Lee JE, Hong SH, et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study[J]. BMC Cancer, 2019, 19(1): 1100. DOI: 10.1186/s12885-019-6267-z. pmid: 31718585
[31]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97. DOI: 10.1126/science.aan3706. pmid: 29097494
[32]	Wang H, Rong X, Zhao G, et al. The microbial metabolite trime-thylamine N-oxide promotes antitumor immunity in triple-negative breast cancer[J]. Cell Metab, 2022, 34(4): 581-594.e8. DOI: 10.1016/j.cmet.2022.02.010. pmid: 35278352
[33]	Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J]. Science, 2017, 357(6356): 1156-1160. DOI: 10.1126/science.aah5043. pmid: 28912244